Mild Matters: A Survey of US Haematologists on the Diagnosis and Management of Individuals With Mild Haemophilia

M.Y.L reports receiving honorarium for participation in advisory boards for Sanofi, Takeda, Hema Biologics and BioMarin. J.M.J. works in the genotyping lab at Bloodworks, which does testing for 8Check (supported by Octapharma) and the Hemophilia Alliance Testing Program. J.M.J. receives research funding and honoraria from Octapharma to the University of Washington and J.M.J. is the contact PI for the Hemophilia A Research Program (HARP), which receives research funding support to RTI International from Hemophilia Alliance and educational funding from Sanofi. G.S.H reports receiving honorarium for participation in advisory boards for Sanofi and educational videos for Novo Nordisk and Sanofi. G.S.H. has also received honoraria from Genentech and Pfizer to the Hemophilia Federation of America for advisory board participation. M.C. receives research funding from Genetech Inc., Novartis Inc., the Children's Foundation of Michigan and Agios Pharmaceuticals. M.C. also reports honoraria for participation in advisory and/or speakers bureau for Novo Nordisk Inc., Kedrion, Takeda, Hema Biologics, CSL Behring, Sanofi and Octapharma. K.B.F., K.C.A. and J.C. report no conflict of interest. For original data, please contact Kerry B. Funkhouser, the FWGBD Executive Director. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.